HC Wainwright reiterated their buy rating on shares of ASLAN Pharmaceuticals (NASDAQ:ASLN – Free Report) in a research note released on Tuesday morning, Benzinga reports. HC Wainwright currently has a $9.00 price objective on the stock.
Separately, Piper Sandler reiterated an overweight rating and set a $10.00 price objective (down from $15.00) on shares of ASLAN Pharmaceuticals in a research note on Wednesday, March 13th.
Get Our Latest Analysis on ASLN
ASLAN Pharmaceuticals Price Performance
ASLAN Pharmaceuticals (NASDAQ:ASLN – Get Free Report) last posted its quarterly earnings data on Friday, April 12th. The company reported ($0.78) EPS for the quarter. As a group, analysts anticipate that ASLAN Pharmaceuticals will post -2.68 EPS for the current year.
ASLAN Pharmaceuticals Company Profile
ASLAN Pharmaceuticals Limited, a clinical-stage immunology focused biopharmaceutical company, engages in developing various treatments to transform the lives of patients. The company's clinical portfolio comprises ASLAN004, a monoclonal antibody that targets the IL-13 receptor a1 subunit which is being developed for the treatment of atopic dermatitis and other immunology indications; and ASLAN003, a small-molecule inhibitor of dihydroorotate dehydrogenase for the treatment of autoimmune diseases.
Featured Stories
- Five stocks we like better than ASLAN Pharmaceuticals
- What Are Dividend Challengers?
- Hasbro’s Management Made All the Right Calls This Quarter
- The Significance of a Trillion-Dollar Market Cap Goes Beyond a Number
- Caterpillar’s Market Reset Isn’t Over: Get Ready for Lower Prices
- What is a SEC Filing?
- Power Surge: Utilities Sector’s Resilience Shines
Receive News & Ratings for ASLAN Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ASLAN Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.